The object of this trial is to assess the safety and efficacy of a 24 week course of flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
1,090
patients will be randomized to flibanserin or placebo in a double-blind manner
patients will be randomized to flibanserin or placebo in a double-blind manner
The Change From Baseline to Week 24 in the Score of the Female Sexual Function Index Desire Domain.
The FSFI is a self-administered questionnaire for assessing key dimensions of sexual function in women. The scale consists of 19 items assessing sexual function over the past 4 weeks and yields scores in 6 domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The 2 items in the desire domain are scored from '1' to '5'. The raw scores of the 2 items are added together and then multiplied by the domain factor of 0.6. Thus, the score of the desire domain ranges from 1.2 to 6.0. The higher the score on the desire domain, the higher the level of reported sexual desire.
Time frame: 24 weeks
Change From Baseline in the SSE Count From Baseline to 24 Weeks
The change from baseline in the number of Satisfying Sexual Events (SSEs) as measured by the eDiary. The SSEs will be standardized to a 28-day period according to the below formula: Total monthly events = 28 x (sum of the number of events) / (sum of number of days entered). "Satisfying" means gratifying, fulfilling, satisfactory, and/or successful for the patient. The partner's satisfaction is not the subject of this question. An eDiary was used by the patients to record information about sexual events. Patients were instructed to complete the eDiary every morning. When completing an eDiary entry, patients answered questions regarding their sexual events since their last eDiary entry. If patients missed or were late with their eDiary entry, they entered information about their sexual events covering a maximum time period of the past 7 days; however, they did not enter any information beyond the last entry.
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
511.147.01074 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
511.147.01046 Boehringer Ingelheim Investigational Site
Huntsville, Alabama, United States
511.147.01042 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
511.147.01025 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
511.147.01073 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
511.147.01030 Boehringer Ingelheim Investigational Site
Encinitas, California, United States
511.147.01028 Boehringer Ingelheim Investigational Site
Fair Oaks, California, United States
511.147.01037 Boehringer Ingelheim Investigational Site
Irvine, California, United States
511.147.01022 Boehringer Ingelheim Investigational Site
Sacramento, California, United States
511.147.01035 Boehringer Ingelheim Investigational Site
San Diego, California, United States
...and 65 more locations